Associate Professor of Neuroradiology University of Wisconsin SMPH Waunakee, Wisconsin
This presentation will show a few different PET radiotracers for imaging of brain tumors, including meningioma, glioma, and brain metastases. First, the concept of radionuclide theranostics agent will be introduced. Then, the targeting mechanism specific to the tumor type will be discussed followed by example cases of the brain tumors and their appearance on hybrid PET/MR imaging. Finally, the potential for inclusion of a theranostics agent will be discussed for each type of brain tumor.
Learning Objectives:
Discuss why PET is complementary to brain MRI in the management of brain tumor patients
Understand examples of PET radiotracers for clinical care or those nearing the clinic.
recognize the difference between radiation therapy delivered externally and radionuclide therapy delivered intravenously
Discuss the partner radionuclides for brain tumor theranostics that are coupled with PET imaging agents.
appreciate how molecular imaging with PET as an example allows for personalized medicine
